To order chemicals, medical devices, or other restricted products please provide ID that includes your business name & shipping address via email CMD_NA@vwr.com or fax 484.881.5997 referencing your VWR account number. Acceptable forms of ID are:
- • State issued document with your organization's Federal Tax ID Number
- • State issued document with your organization's Resale Tax ID Number
- • City or County issued Business License
- • State Department of Health Services License
- • Any other ID issued by the State that includes the business name & address
* ATTN: California Customers may require additional documentation as part of the CA Health & Safety Code. Products that fall under this regulation will be placed on a mandatory 21-day hold after documentation is received. Avantor will not lift restrictions for residential shipping addresses.
- Protein/Peptide Type:Native
- Source:Plasma
- Species:Human
- Size:1 mg
- Environmentally Preferable:
- Reconstitution Instructions:In water or aqueous buffer
- Protein Synonyms:A2M|A broad-spectrum protease-binding protein|C3 and PZP-like alpha-2-macroglobulin domain-containing protein 5|inhibition of amyloid formation
- Protein/Peptide Name:alpha-2-Macroglobulin
- Purity:>95%
- Molecular Weight:725 kDa
- Formulation:Lyophilized from 100 mM Na Phosphate, pH 7.2.
- Cat. No.:10009-744
- Supplier no.:7297-1000
≥ 95% pure native Alpha 2 Macroglobulin Protein isolated from human plasma
Alpha 2 Macroglobulin (A2M) is a plasma protease inhibitor which has been shown to exist in two forms. The Slow Form of A2M (S-A2M) is the form which possesses the ability to bind and inhibit proteases by a “trap” method. The Fast Form of A2M (F-A2M) is generated when S-A2M undergoes a conformational change due to either entrapment of a protease in the A2M bait region, or chemical cleavage of an internal thiol ester bond located near the bait region. F-A2M does not possess the ability to bind and inhibit protease activity. F-A2M is rapidly taken up by the liver, with a half-life of 2-4 minutes. In vivo, F-A2M typically represents only 0.17–0.7% of the total A2M in blood plasma of adults. The F-A2M plasma concentration is, however, increased in many disease states including pancreatitis, multiple sclerosis and sepsis. F-A2M has also been implicated in the inhibition of amyloid formation associated with Alzheimer’s disease and spongiform encephalopathy.